Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
KW Beekman, AD Colevas, K Cooney… - Clinical genitourinary …, 2006 - Elsevier
Two randomized trials demonstrated an improvement in survival with docetaxel-based
chemotherapy for patients with metastatic, androgenindependent prostate disease.
However, the effect of current therapy is suboptimal in that it is complicated by toxicities and
has no curative potential. Cilengitide (EMD121974; NSC 707544), is a potent selective αvβ3
and αvβ5 integrin antagonist. Integrins are cell surface receptors that mediate a variety of
cell activities including endothelial cell proliferation and migration. Blocking the ligation of …
chemotherapy for patients with metastatic, androgenindependent prostate disease.
However, the effect of current therapy is suboptimal in that it is complicated by toxicities and
has no curative potential. Cilengitide (EMD121974; NSC 707544), is a potent selective αvβ3
and αvβ5 integrin antagonist. Integrins are cell surface receptors that mediate a variety of
cell activities including endothelial cell proliferation and migration. Blocking the ligation of …